Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review

Overview

Journal Nutrients

Date 2018 May 23

PMID 29783752

Citations 82

Authors

Gautam Sethi

Muthu K Shanmugam

Sudha Warrier

Myriam Merarchi

Frank Arfuso

Alan Prem Kumar

Anupam Bishayee

Affiliations

Soon will be listed here.

Abstract

Novel and alternative options are being adopted to combat the initiation and progression of human cancers. One of the approaches is the use of molecules isolated from traditional medicinal herbs, edible dietary plants and seeds that play a pivotal role in the prevention/treatment of cancer, either alone or in combination with existing chemotherapeutic agents. Compounds that modulate these oncogenic processes are potential candidates for cancer therapy and may eventually make it to clinical applications. Diosgenin is a naturally occurring steroidal sapogenin and is one of the major bioactive compounds found in dietary fenugreek () seeds. In addition to being a lactation aid, diosgenin has been shown to be hypocholesterolemic, gastro- and hepato-protective, anti-oxidant, anti-inflammatory, anti-diabetic, and anti-cancer. Diosgenin has a unique structural similarity to estrogen. Several preclinical studies have reported on the pro-apoptotic and anti-cancer properties of diosgenin against a variety of cancers, both in in vitro and in vivo. Diosgenin has also been reported to reverse multi-drug resistance in cancer cells and sensitize cancer cells to standard chemotherapy. Remarkably, diosgenin has also been reported to be used by pharmaceutical companies to synthesize steroidal drugs. Several novel diosgenin analogs and nano-formulations have been synthesized with improved anti-cancer efficacy and pharmacokinetic profile. In this review we discuss in detail the multifaceted anti-cancer properties of diosgenin that have found application in pharmaceutical, functional food, and cosmetic industries; and the various intracellular molecular targets modulated by diosgenin that abrogate the oncogenic process.

Citing Articles

Exploring the molecular mechanism of L. for the treatment of menstrual disorders using network pharmacology and molecular docking.

Silambarasan R, Kasthuri Nair A, Maniyan G, Vijaya R, Nair R, Hareendran Nair J Heliyon. 2025; 11(4):e42582.

PMID: 40028534 PMC: 11870275. DOI: 10.1016/j.heliyon.2025.e42582.

Potent Anti-Cancer Activity of 1-Dehydrodiosgenone from the Product of Microbial Transformation of Steroid Saponins.

Li Q, Feng S, Zhang Y, Mou F, Guo T, Qin B Int J Mol Sci. 2024; 25(23).

PMID: 39684828 PMC: 11641788. DOI: 10.3390/ijms252313118.

Effect of Diosgenin in Suppressing Viability and Promoting Apoptosis of Human Prostate Cancer Cells: An Interplay with the G Protein-Coupled Oestrogen Receptor?.

Figueira M, Marques R, Cardoso H, Fonseca L, Duarte A, Silvestre S Int J Mol Sci. 2024; 25(22).

PMID: 39596074 PMC: 11593390. DOI: 10.3390/ijms252212006.

The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Figueira M, Carvalho T, Macario-Monteiro J, Cardoso H, Correia S, Vaz C Biomedicines. 2024; 12(8).

PMID: 39200101 PMC: 11351860. DOI: 10.3390/biomedicines12081636.

Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.

Cui N, Ding F Drug Des Devel Ther. 2024; 18:3157-3173.

PMID: 39071813 PMC: 11283265. DOI: 10.2147/DDDT.S458613.

References

Steeg P . Targeting metastasis. Nat Rev Cancer. 2016; 16(4):201-18. PMC: 7055530. DOI: 10.1038/nrc.2016.25. View

El Bairi K, Ouzir M, Agnieszka N, Khalki L . Anticancer potential of Trigonella foenum graecum: Cellular and molecular targets. Biomed Pharmacother. 2017; 90:479-491. DOI: 10.1016/j.biopha.2017.03.071. View

Chaffer C, Weinberg R . How does multistep tumorigenesis really proceed?. Cancer Discov. 2015; 5(1):22-4. PMC: 4295623. DOI: 10.1158/2159-8290.CD-14-0788. View

Sanchez-Sanchez L, Hernandez-Linares M, Escobar M, Lopez-Munoz H, Zenteno E, Fernandez-Herrera M . Antiproliferative, Cytotoxic, and Apoptotic Activity of Steroidal Oximes in Cervicouterine Cell Lines. Molecules. 2016; 21(11). PMC: 6273349. DOI: 10.3390/molecules21111533. View

Ahn K, Sethi G, Aggarwal B . Nuclear factor-kappa B: from clone to clinic. Curr Mol Med. 2007; 7(7):619-37. DOI: 10.2174/156652407782564363. View

Chen P, Shih Y, Huang H, Cheng H . Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One. 2011; 6(5):e20164. PMC: 3100339. DOI: 10.1371/journal.pone.0020164. View

Cragg G, Grothaus P, Newman D . Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009; 109(7):3012-43. DOI: 10.1021/cr900019j. View

Patel K, Gadewar M, Tahilyani V, Patel D . A review on pharmacological and analytical aspects of diosmetin: a concise report. Chin J Integr Med. 2013; 19(10):792-800. DOI: 10.1007/s11655-013-1595-3. View

Shanmugam M, Lee J, Chai E, Mathi Kanchi M, Kar S, Arfuso F . Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin Cancer Biol. 2016; 40-41:35-47. DOI: 10.1016/j.semcancer.2016.03.005. View

10.

Folkman J . Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007; 6(4):273-86. DOI: 10.1038/nrd2115. View

11.

He Z, Chen H, Li G, Zhu H, Gao Y, Zhang L . Diosgenin inhibits the migration of human breast cancer MDA-MB-231 cells by suppressing Vav2 activity. Phytomedicine. 2014; 21(6):871-6. DOI: 10.1016/j.phymed.2014.02.002. View

12.

Masood-Ur-Rahman , Mohammad Y, Fazili K, Bhat K, Ara T . Synthesis and biological evaluation of novel 3-O-tethered triazoles of diosgenin as potent antiproliferative agents. Steroids. 2016; 118:1-8. DOI: 10.1016/j.steroids.2016.11.003. View

13.

Shishodia S, Aggarwal B . Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene. 2005; 25(10):1463-73. DOI: 10.1038/sj.onc.1209194. View

14.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

15.

Jesus M, Martins A, Gallardo E, Silvestre S . Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology. J Anal Methods Chem. 2017; 2016:4156293. PMC: 5225340. DOI: 10.1155/2016/4156293. View

16.

Kim J, Park S . An update on the biological and pharmacological activities of diosgenin. EXCLI J. 2018; 17:24-28. PMC: 5780621. DOI: 10.17179/excli2017-894. View

17.

Li F, Fernandez P, Rajendran P, Hui K, Sethi G . Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010; 292(2):197-207. DOI: 10.1016/j.canlet.2009.12.003. View

18.

Mishra K, Ganju L, Sairam M, Banerjee P, Sawhney R . A review of high throughput technology for the screening of natural products. Biomed Pharmacother. 2007; 62(2):94-8. DOI: 10.1016/j.biopha.2007.06.012. View

19.

Newman D, Cragg G . Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. Mar Drugs. 2017; 15(4). PMC: 5408245. DOI: 10.3390/md15040099. View

20.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View